share_log

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN): Is Breakeven Near?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN): Is Breakeven Near?

第一天生物製藥公司(納斯達克:DAWN):盈虧平衡近了嗎?
Simply Wall St ·  01/14 11:28

With the business potentially at an important milestone, we thought we'd take a closer look at Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) future prospects. Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. With the latest financial year loss of US$189m and a trailing-twelve-month loss of US$84m, the US$1.2b market-cap company alleviated its loss by moving closer towards its target of breakeven. The most pressing concern for investors is Day One Biopharmaceuticals' path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

考慮到業務可能處於一個重要的里程碑,我們認爲有必要仔細研究一下第一天生物製藥公司(納斯達克:DAWN)的未來前景。第一天生物製藥公司是一家臨牀階段的生物製藥公司,專注於爲患有基因組定義癌症的患者開發和商業化靶向療法。 在最新的財務年度虧損爲18900萬美元,過去十二個月的虧損爲8400萬美元的情況下,這家市值12億美元的公司通過朝着盈利目標更進一步而減輕了其損失。 投資者最迫切關心的是第一天生物製藥通往盈利的路徑——它何時能夠實現盈虧平衡?我們整理了一份行業分析師對公司的預期,包括其盈虧平衡年份和隱含的增長率。

Day One Biopharmaceuticals is bordering on breakeven, according to the 10 American Biotechs analysts. They anticipate the company to incur a final loss in 2026, before generating positive profits of US$47m in 2027. The company is therefore projected to breakeven around 2 years from today. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 52% is expected, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

根據10位美國生物技術分析師的預測,第一天生物製藥公司即將實現盈虧平衡。他們預計該公司將在2026年經歷最後的虧損,隨後在2027年實現4700萬美元的正利潤。因此,該公司預計將在大約2年後實現盈虧平衡。 爲了達到這一盈虧平衡日期,我們計算了該公司必須年年增長的速率。結果顯示,預計年均增長率爲52%,這相當強勁。如果這個增長率過於激進,公司的盈利能力可能會比分析師預期的晚得多。

big
NasdaqGS:DAWN Earnings Per Share Growth January 14th 2025
納斯達克GS:DAWN 每股收益增長2025年1月14日

We're not going to go through company-specific developments for Day One Biopharmaceuticals given that this is a high-level summary, though, take into account that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

由於這是一個高層次的總結,我們不打算深入探討第一天生物製藥公司的具體發展,不過請考慮到,生物技術公司通常在產品開發階段的現金流波動性較大。因此,高增長率並不鮮見,特別是當一家公司處於投資期時。

Before we wrap up, there's one aspect worth mentioning. Day One Biopharmaceuticals currently has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which usually has a high level of debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.

在結束之前,有一個值得提及的方面。第一天生物製藥公司目前在其資產負債表上沒有債務,這對於一家現金燃燒型生物技術公司來說相當不尋常,通常這類公司相對於其股本會有較高的債務水平。這意味着該公司完全依靠其股權投資進行運營,沒有債務負擔。這個因素降低了投資於這一虧損公司的風險。

Next Steps:

下一步:

There are too many aspects of Day One Biopharmaceuticals to cover in one brief article, but the key fundamentals for the company can all be found in one place – Day One Biopharmaceuticals' company page on Simply Wall St. We've also compiled a list of relevant factors you should further examine:

關於Day One生物製藥公司的方面有很多,無法在一篇簡短的文章中詳細介紹,但這個公司的關鍵基本面可以在一個地方找到——Day One生物製藥公司在Simply Wall ST的公司頁面。我們還編制了一份相關因素的列表,您應該進一步考察:

  1. Valuation: What is Day One Biopharmaceuticals worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Day One Biopharmaceuticals is currently mispriced by the market.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Day One Biopharmaceuticals's board and the CEO's background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
  1. 估值:今天的Day One生物製藥公司值多少錢?未來的增長潛力是否已經反映在價格中?我們免費研究報告中的內在價值信息圖幫助可視化當前市場是否對Day One生物製藥公司定價錯誤。
  2. 管理團隊:經驗豐富的管理團隊能增加我們對業務的信心——看看Day One生物製藥公司的董事會成員以及CEO的背景。
  3. 其他高表現股票:是否還有其他股票提供更好的前景和經過驗證的業績?在這裏查看我們這些優秀股票的免費列表。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
1
評論 評論 · 瀏覽 239

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。